Time filter

Source Type

Craiova, Romania

Militaru C.,Craiova Cardiology Center | Donoiu I.,University of Medicine and Pharmacy of Craiova | Craciun A.,Craiova Cardiology Center | Scorei I.D.,Neuropsychiatry Hospital | And 2 more authors.
Nutrition | Year: 2013

Objective: This study aimed to evaluate the effects of short-term (60-d) oral supplementation with calcium fructoborate, resveratrol, and their combination on the clinical and biological statuses of subjects with stable angina pectoris. Methods: A randomized, double-blinded, active-controlled, parallel clinical trial was conducted in three groups of subjects. Of the total number of subjects included in study (n = 166), 87 completed the 60-d test treatment study period and 29 followed in parallel their usual medical care and treatment. The primary outcomes were inflammation biomarkers (high-sensitivity C-reactive protein), left ventricular function markers (N-terminal prohormone of brain natriuretic peptide), and lipid markers (total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triacylglycerols). Quality of life was assessed by the Canadian Cardiovascular Society angina class and the number of angina attacks per week. Results: There was a significant decrease of high-sensitivity C-reactive protein in all groups at the 30-d and 60-d visits. This decrease was greater (39.7% at 60 d) for group 3 (calcium fructoborate), followed by group 2 (resveratrol plus calcium fructoborate, 30.3% at 60 d). The N-terminal prohormone of brain natriuretic peptide was significantly lowered by resveratrol (group 1, 59.7% at 60 d) and by calcium fructoborate (group 3, 52.6% at 60 d). However, their combination (group 2) was the most effective and induced a decrease of 65.5%. Lipid markers showed slight changes from baseline in all groups. The improvement in the quality of life was best observed for subjects who received the resveratrol and calcium fructoborate mixture (group 2). Conclusion: The results indicate that the combination of resveratrol and calcium fructoborate has beneficial effects in patients with angina (ClinicalTrials.gov, ISRCTN02337806; March 25, 2010). © 2013 Elsevier Inc. Source

Bicu D.,Neuropsychiatry Hospital | Bondari A.,University of Medicine and Pharmacy of Craiova | Bicu M.,Diabetes | Tapu F.,Clinical County Emergency Hospital
Archives of the Balkan Medical Union | Year: 2010

Background: Multiple sclerosis is the most common neurological disease in young adults characterized by recurrent relapses and/or progression within the central nervous system. Method: The study was realized on a group made up of 26 patients with relapsing - remitting multiple sclerosis, 10 men and 16 women, a man of 35.1 ± 5.1 years, that suffers from a disease for 5.6 ± 3.1 years, clinically and imagistically monitored. MS-related disability was clinically assessed using the Expanded Disability Status Scale and Multiple Sclerosis Functional Composite. The imagistic exploration proved its efficiency in completing these methods, representing a sensitive method in sustaining the assessment and progression of disease. Results: Multiple Sclerosis Functional Composite is a good method for assessing the evolution of the disease, a more sensitive one than the Expanded Disability Status Scale, it can reflect with high sensitivity clinical changes and cognitive dysfunctions. Magnetic resonance imaging points out the activity of the disease, new lesions on T1 or T2-weighted sequences appear more frequently than they are detected clinically, presenting clearer advantages for the assessment and therapeutic monitoring. Conclusions: The imagistic parameters together with the clinical markers represent important criteria to sustain the evolution and the progression of the disease. Copyright © 2010 Celsius. Source

Bicu D.,Neuropsychiatry Hospital | Bondari A.,University of Sfax | Trifan F.,University of Sfax
Archives of the Balkan Medical Union | Year: 2010

Multiple sclerosis represents a chronic inflammatory and degenerative disease of the central nervous system, that affects the young adult with still unknown etiology. We are given the case of two sister patients, diagnosed with recurrent remissive multiple sclerosis in 2001, respectively in 2006. In the first case, the presence of relapses, but also Magnetic resonance imaging modifications allowed the establishment of the diagnosis and the beginning of the imunomodulator treatment. Despite the imunomodulator treatment and of the autologous stem cell transplantation, the evolution of the disease was unfavorable In the second case, in a first stage an antiphospholipid syndrome was suspected, but further clinical evolution and laboratory tests infirmed the diagnosis. The presence of relapses, but also of the imagistic modifications lead to recurrent remissive multiple sclerosis diagnosis, with an favorable evolution under imunomodulator treatment. The clinical evaluation was made with Expanded Disability Status Scale, and the imagistic was based on Magnetic resonance imaging sequences. Copyright © 2010 CELSIUS. Source

Pintea I.L.,University of Medicine and Pharmacy of Craiova | Rolea E.,University of Medicine and Pharmacy of Craiova | Balseanu A.T.,University of Medicine and Pharmacy of Craiova | Pirici I.,Neuropsychiatry Hospital | And 2 more authors.
Romanian Journal of Morphology and Embryology | Year: 2011

Reduced cerebral blood flow beyond the compensatory mechanisms leads to cerebral hypoxia. Hypoxia causes various lesions of neurons, glial cells and cerebral blood vessels, depending on its duration and intensity. In our study, we reduced cerebral blood flow in the experience animal on average by 30%, by right internal carotid artery ligation. Fifteen days after the onset of hypoxia, by histology and immunohistochemical studies, we identified neuronal, glial and vascular damage. Lesions of nerve and glial cells ranged from changes of cytoplasmic tinting with the development of "red neurons", to neuronal and glial cytolysis with areas of focal necrosis. Vascular lesions were represented by the collapse, fragmentation and discontinuity of capillaries, always associated with a marked perivascular edema. Source

Scorei R.,University of Craiova | Mitrut P.,University of Medicine and Pharmacy of Craiova | Petrisor I.,University of Craiova | Scorei I.,Neuropsychiatry Hospital
Biological Trace Element Research | Year: 2011

The objective of this pilot study was to determine whether 15 days of dietary supplementation with calcium fructoborate could acutely modulate inflammatory and lipid blood markers in individuals diagnosed with primary osteoarthritis. During 2 weeks, a placebocontrolled, randomized, double-blind study was conducted on 116 subjects that were initially recruited. Seventy-two subjects started the study, being divided into four groups, and only 60 completed the study as designed. The aim was to compare the effects of calciumfructoborate to placebo on subjects diagnosed with knee primary osteoarthritis. The obtained outcomes were inflammation biomarkers (C-reactive protein, fibrinogen, and erythrocyte sedimentation rate) and lipid markers (triglycerides, total cholesterol, LDL cholesterol, and HDL cholesterol). No serious adverse events were reported. The calcium fructoborate showed beneficial effect on the inflammatory markers for all groups subjected to the treatment when compared with the placebo group and slight changes in the lipid metabolism. This study suggests that short-term (2 weeks) calcium fructoborate supplementation in patients with osteoarthritis symptoms has a favorable prognosis on inflammation diseases. © Springer Science+Business Media, LLC 2011. Source

Discover hidden collaborations